September 27th (Eastern Time) - $Brainstorm Cell Therapeutics (BCLI.US)$ is about to implement a 1-for-15 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from October 1st, 2024.
$Brainstorm Cell Therapeutics (BCLI.US)$ rose 4.26% and closed at $0.2545 on September 26th with a turnover of $44,603. $Brainstorm Cell Therapeutics (BCLI.US)$ now has a total market capitalization of $20.29 million.
What Is a Reverse Stock Split?
A reverse stock split consolidates the number of existing shares of stock held by shareholders into fewer shares. It does not directly impact a company's value. And it can signal a company in distress since it raises the value of otherwise low-priced shares.
Note:
The company's actual implementation is subject to the final disclosure submitted to the exchange. The information provided herein is for reference only.